Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capravirine + nelfinavir + lamivudine + zidovudine
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug is an **antiretroviral combination regimen** consisting of four agents: capravirine (a non-nucleoside reverse transcriptase inhibitor, NNRTI), nelfinavir (a protease inhibitor), lamivudine (a nucleoside reverse transcriptase inhibitor, NRTI), and zidovudine (another NRTI). Together, these medications are designed to inhibit HIV replication at multiple stages: capravirine blocks reverse transcriptase by a non-nucleoside mechanism, nelfinavir inhibits viral protease preventing processing of viral proteins, and both lamivudine and zidovudine inhibit reverse transcriptase as nucleoside analogues, blocking DNA synthesis. This combination was investigated for use in HIV-infected individuals—particularly those who failed initial combination therapy—providing broad and multi-targeted suppression of viral replication. Capravirine was developed by Agouron Pharmaceuticals and tested in clinical trials with this combination[3][8]. Nelfinavir is developed and manufactured by Agouron Pharmaceuticals and Abbott (now mainly Pfizer); lamivudine and zidovudine are manufactured by multiple companies, notably ViiV Healthcare (for Combivir).
- Brand names
- Viracept (for nelfinavir)Combivir (for lamivudine + zidovudine)
- Other names
- capravirine + nelfinavir + lamivudine + zidovudine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptasePR (Progesterone receptor)
Beyond the preview
Go deeper on capravirine + nelfinavir + lamivudine + zidovudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capravirine + nelfinavir + lamivudine + zidovudine.